Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy")

Journal of Neuroscience

Volumn 28, Issue 12, 2008, Pages 3234-3245

  Busceti, Carla L ^a   Biagioni, Francesca ^a   Riozzi, Barbara ^a   Battaglia, Giuseppe ^a   Storto, Marianna ^a   Cinque, Carlo ^b   Molinaro, Gemma ^a   Gradini, Roberto ^b   Caricasole, Andrea ^c   Canudas, Anna Maria ^d   Bruno, Valeria ^a,b   Nicoletti, Ferdinando ^a,b   Fornai, Francesco ^a,e  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Siena Biotech SpA   (Italy)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

Cdk5; Dickkopf 1; Hippocampus; MDMA; Neurotoxicity; Tau phosphorylation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN DICKKOPF 1; PROTEIN P25; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; WNT PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLIOSIS; HIPPOCAMPUS; LEARNING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CYCLIN-DEPENDENT KINASE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HALLUCINOGENS; HIPPOCAMPUS; IMMUNOPRECIPITATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEARNING; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, MUTANT STRAINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TAU PROTEINS; WAKEFULNESS;

EID: 41149155241     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0159-08.2008     Document Type: Article

References (93)

1. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94:239-247.
2. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797-3804.
3. Adamska M, MacDonald BT, Meisler MH (2003) Doubleridge, a mouse mutant with defective compaction of the apical ectodermal ridge and normal dorsal-ventral patterning of the limb. Dev Biol 255:350-362.
4. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 91:5562-5566.
5. Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2:783-787.
6. Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K (1997) Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 94:298-303.
7. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K (2006) Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci USA 103:8864-8869.
8. Baumann MH, Wang X, Rothman RB (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407-424.
9. Bjarkam CR, Sorensen JC, Geneser FA (2003) Distribution and morphology of serotonin-immunoreactive axons in the hippocampal region of the New Zealand white rabbit. I. Area dentata and hippocampus. Hippocampus 13:21-37.
10. Busceti CL, Biagioni F, Aronica E, Riozzi B, Storto M, Battaglia G, Giorgi FS, Gradini R, Fornai F, Caricasole, Nicoletti F, Bruno V (2007) Induction of the Wnt inhibitor, Dickkopf-1, is associated with neurodegeneration related to temporal lobe epilepsy. Epilepsia 48:694-705.
11. Cadet JL, Ladenheim B, Baum I, Carlson E, Epstein C (1994) CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res 655:259-262.
12. Cadet JL, Ladenheim B, Hirata H, Rothman RB, Ali S, Carlson E, Epstein C, Moran TH (1995) Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 21:169-176.
13. Cadet JL, Thiriet N, Jayanthi S (2001) Involvement of free radicals in MDMA-induced neurotoxicity in mice. Ann Med Interne (Paris) 152 [Suppl 3]:IS57-IS59.
14. Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11:183-202.
15. Capela JP, Fernandes E, Remião F, Bastos ML, Meisel A, Carvalho F (2007) Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. Neurotoxicology 28:868-875.
16. Cappuccio I, Calderone A, Busceti CL, Biagioni F, Pontarelli F, Bruno V, Storto M, Terstappen GT, Gaviraghi G, Fornai F, Battaglia G, Melchiorri D, Zukin RS, Nicoletti F, Caricasole A (2005) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci 25:2647-2657.
17. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F (2004) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 24:6021-6027.
18. Cerruti C, Sheng P, Ladenheim B, Epstein CJ, Cadet JL (1995) Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro. Clin Exp Pharmacol Physiol 22:381-382.
19. Chen J, Zhang Y, Kelz MB, Steffen C, Ang ES, Zeng L, Nestler EJ. (2000) Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of ΔFosB. J Neurosci 20:8965-8971.
20. Colado MI, Granados R, O'Shea E, Esteban B, Green AR (1999) The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy"). Pharmacol Toxicol 84:261-266.
21. Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, Green AR (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on dopamine neurones in mouse brain. Br J Pharmacol 134:1711-1723.
22. Crespo-Biel N, Camins A, Pelegrí C, Vilaplana J, Pallàs M, Canudas AM (2007) 3-Nitropropionic acid activates calpain/cdk5 pathway in rat striatum. Neurosci Lett 421:77-81.
23. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40:471-483.
24. Dafters RI, Duffy F, O'Donnell PJ, Bouquet C (1999) Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology 145:82-90.
25. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, Gouzoulis-Mayfrank E (2005) Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology 180:607-611.
26. Dhavan R, Tsai LH (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2:749-759.
27. Elayan I, Gibb JW, Hanson GR, Foltz RL, Lim HK, Johnson M (1992) Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5- methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine. Eur J Pharmacol 221:281-288.
28. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI (2001) 3,4-Methylendioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154:251-260.
29. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates, Ed 2. New York: Academic.
30. Frenzilli G, Ferrucci M, Giorgi FS, Blandini F, Nigro M, Ruggieri S, Murri L, Paparelli A, Fornai F (2007) DNA fragmentation and oxidative stress in the hippocampal formation: a bridge between 3,4-methylenedioxymethamphetamine (ecstasy) intake and long-lasting behavioural alterations. Behav Pharmacol 18:471-481.
31. Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX (2000) Mood state and brain electric activity in ecstasy users. NeuroReport 11:157-162.
32. Giorgi FS, Pizzanelli C, Ferrucci M, Lazzeri G, Faetti M, Giusiani M, Pontarelli F, Busceti CL, Murri L, Fornai F (2005) Previous exposure to (±)3,4-methylenedioxymethamphetamine produces long-lasting alteration in limbic brain excitability measured by electroencephalogram spectrum analysis, brain metabolism and seizure susceptibility. Neuroscience 136:43-53.
33. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K (2006) Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol 2006:31825.
34. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508.
35. Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acidtreated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267:564-569.
36. Gruart A, Munoz MD, Delgado-Garcia JM (2006) Involvement of the CA3-CA1 synapse in the acquisition of associative learning in behaving mice. J Neurosci 26:1077-1087.
37. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:4913-4917.
38. Harada T, Morooka T, Ogawa S, Nishida E (2001) ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol 3:453-459.
39. Hinck L, Nelson WJ, Papkoff J (1994) Wnt-1 modulates cell-cell adhesion in mammalian cells by stabilizing β-catenin binding to the cell adhesion protein cadherin. J Cell Biol 124:729-741.
40. Hisanaga S, Saito T (2003) The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Neurosignals 12:221-229.
41. Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M (2007) Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res 1130:206-213.
42. Iqbal K, Grundke-Iqbal I, Smith AJ, George L, Tung YC, Zaidi T (1989) Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease. Proc Natl Acad Sci USA 86:5646-5650.
43. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH (2004) Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology 173:383-390.
44. Jayanthi S, Ladenheim B, Andrews AM, Cadet JL (1999) Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). Neuroscience 91:1379-1387.
45. Johnson M, Bush LG, Hanson GR, Gibb JW (1993) Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decreasein striatal serotonin concentration and on the increase in striatal neurotens in and dynorphin A concentrations. Biochem Pharmacol 46:770-772.
46. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttilä T (2004) Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons. Neurosci Lett 368:181-185.
47. Klein SP, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93:8455-8459.
48. Knockaert M, Greengard P, Meijer L (2002) Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23:417-425.
49. Lee JH, Kim KT (2004) Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells. J Neurochem 91:634-647.
50. Lee MS, Tsai LH (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis 5:127-137.
51. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360-364.
52. Lee VM, Balin BJ, Otvos Jr L, Trojanowski JQ (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251:675-678.
53. Liao X, Zhang Y, Wang Y, Wang J (2004) The effect of cdk-5 overexpression on tau phosphorylation and spatial memory of rat. Sci China C Life Sci 47:251-257.
54. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong CX (2006a) PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett 580:6269-6274.
55. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ (2006b) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87:1333-1344.
56. Logan BJ, Laverty R, Sanderson WD, Yee YB (1998) Differences between rats and mice in MDMA (methylendioxynethylamphetamine) neurotoxicity. Eur J Pharmacol 152:227-234.
57. Lyles J, Cadet JL (2003) Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Brain Res Rev 42:155-168.
58. MacDonald BT, Adamska M, Meisler MH (2004) Hypomorphic expression of Dkk1 in the doubleridge mouse: dose dependence and compensatory interactions with Lrp6. Development 131:2543-2552.
59. Mann H, Ladenheim B, Hirata H, Moran TH, Cadet JL (1997) Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res 769:340-346.
60. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437.
61. Miranda M, Bosch-Morell F, Johnsen-Soriano S, Barcia J, Almansa I, Asensio S, Araiz J, Messeguer A, Romero FJ (2007) Oxidative stress in rat retina and hippocampus after chronic MDMA ("ecstasy") administration. Neurochem Res 32:1156-1162.
62. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
63. Nath R, Davis M, Probert AW, Kupina NC, Ren X, Schielke GP, Wang KK (2000) Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun 274:16-21.
64. Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:7469-7481.
65. O'Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
66. O'Shea A, Esteban B, Camarero J, Green AR, Colado MI (2001) Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ("ecstasy") on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40:65-74.
67. O'Shea E, Sanchez V, Orio L, Escobedo I, Green AR, Colado MI (2005) 3,4-Methylenedioxymethamphetamine increases pro-interleukin-1beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: role of interleukin-1beta in neurotoxicity. Neuroscience 135:1095-1105.
68. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-622.
69. Patzke H, Tsai LH (2002) Cdk5 sinks into ALS. Trends Neurosci 25:8-10.
70. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56:70-78.
71. Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B, Cowburn RF (1998) Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 797:267-277.
72. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58:1010-1019.
73. Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281:25457-25465.
74. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR (2004) Effect of repeated ("binge") dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol 18:412-416.
75. Schmued LC, Hopkins KJ (2000) Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 874:123-130.
76. Schmued LC, Albertson C, Slikker Jr W (1997) Fluoro-Jade B: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 751:37-46.
77. Sengupta A, Grundke-Iqbal I, Iqbal K (2006) Regulation of phosphorylation of tau by protein kinases in rat brain. Neurochem Res 31:1473-1480.
78. Seo YR, Jung HJ (2004) The potential roles of p53 tumor suppressor in nucleotide excision repair (NER) and base excision repair (BER). Exp Mol Med 36:505-509.
79. Smith ML, Seo YR (2002) p53 regulation of DNA excision repair pathways. Mutagenesis 17:149-156.
80. Stone DM, Hanson GR, Gibb JW (1987) Differences in the central serotonergic effects of methylendioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26:1657-1661.
81. Sun L, Liu SY, Zhou XW, Wang XC, Liu R, Wang Q, Wang JZ (2003) Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118:1175-1182.
82. 3H]-citalopram binding in the CA-3 area of rat hippocampus. Neurosci Lett 335:49-53.
83. Tseng HC, Zhou Y, Shen Y, Tsai LH (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 523:58-62.
84. Wang J, Shou J, Chen X (2000) Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 19:1843-1848.
85. Wang Y, White MG, Akay C, Chodroff RA, Robinson J, Lindl KA, Dichter MA, Qian Y, Mao Z, Kolson DL, Jordan-Sciutto KL (2007) Activation of cyclin-dependent kinase 5 by calpains contributes to human immunodeficiency virus-induced neurotoxicity. J Neurochem 103:439-455.
86. Wesierska-Gadek J, Strosznajder JB, Schmid G (2006) Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors. Mol Neurobiol 34:27-50.
87. Willert K, Nusse R (1998) β-Catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 8:95-102.
88. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92:232-241.
89. Yau JL, Kelly PA, Sharkey J, Seckl JR (1994) Chronic 3,4- methylenedioxymethamphetamine administration decreases glucocorticoid and mineralocorticoid receptor, but increases 5-hydroxytryptamine1C receptor gene expression in the rat hippocampus. Neuroscience 61:31-40.
90. Yeh SY, Dersch C, Rothman R, Cadet JL (1999) Effects of antihistamines on 3, 4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Synapse 33:207-217.
91. Zakzanis KK, Campbell Z (2006) Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 66:740-741.
92. Zakzanis KK, Young DA (2001) Memory impairment in abstinent MDMA ("Ecstasy") users: a longitudinal investigation. Neurology 56:966-969.
93. Zhu Y, Lin L, Kim S, Quaglino D, Lockshin RA, Zakeri Z (2002) Cyclin dependent kinase 5 and its interacting proteins in cell death induced in vivo by cyclophosphamide in developing mouse embryos. Cell Death Differ 9:421-430.